3 results on '"Gurguí, Mercè"'
Search Results
2. Risk Factors, Clinical Features, and Outcomes of Toxoplasmosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study.
- Author
-
Fernàndez-Sabé, Núria, Cervera, Carlos, Fariñas, M. Carmen, Bodro, Marta, Muñoz, Patricia, Gurguí, Mercè, Torre-Cisneros, Julián, Martín-Dávila, Pilar, Noblejas, Ana, Len, Óscar, García-Reyne, Ana, Pozo, JoséLuis Del, and Carratalà, Jordi
- Subjects
TOXOPLASMOSIS ,HEALTH outcome assessment ,TRANSPLANTATION of organs, tissues, etc. ,CASE-control method ,HISTOPATHOLOGY ,CHORIORETINITIS ,BRAIN abscess ,DISEASE risk factors - Abstract
Background. Solid-organ transplant (SOT) recipients are considered to be at increased risk for toxoplasmosis. However, risk factors for this infection have not been assessed. The aim of this study was to determine the risk factors, clinical features, and outcomes of toxoplasmosis in SOT recipients. Methods. A multicenter, matched case-control study (1:2 ratio) was conducted between 2000 and 2009. Control subjects were matched for center, transplant type, and timing. Cases were identified from the hospitals' microbiology and transplantation program databases. Logistic regression was performed to identify independent risk factors. Results. Twenty-two cases (0.14%) of toxoplasmosis were identified among 15 800 SOTs performed in 11 Spanish hospitals, including 12 heart, 6 kidney, and 4 liver recipients. Diagnosis was made by seroconversion (n = 17), histopathologic examination (n = 5), polymerase chain reaction (n = 2), and autopsy (n = 2). In a comparison of case patients with 44 matched control subjects, a negative serostatus prior to transplantation was the only independent risk factor for toxoplasmosis (odds ratio, 15.12 [95% confidence interval, 2.37-96.31]; P 5 .004). The median time to diagnosis following transplantation was 92 days. Primary infection occurred in 18 (81.8%) cases. Manifestations included pneumonitis (n = 7), myocarditis (n = 5), brain abscesses (n = 5), chorioretinitis (n = 3), lymph node enlargement (n = 2), hepatosplenomegaly (n = 2), and meningitis (n =1). Five patients (22.7%) had disseminated disease. Crude mortality rate was 13.6% (3 of 22 patients). Conclusions. Although uncommon, toxoplasmosis in SOT patients causes substantial morbidity and mortality. Seronegative recipients are at high risk for developing toxoplasmosis and should be given prophylaxis and receive careful follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients.
- Author
-
Len, Oscar, Gavaldà, Joan, Aguado, José Maria, Borrell, Nüria, Cervera, Carlos, Cisneros, José Miguel, Cuervas-Mons, Valentin, Gurguí, Mercè, Martin-Dávila, Pilar, Montejo, Miguel, Muñoz, Patricia, Bou, Germán, Carratalà, Jordi, Torre-Cisneros51, Julián, and Pahissa, Albert
- Subjects
VALGANCICLOVIR ,CYTOMEGALOVIRUS diseases ,TRANSPLANTATION of organs, tissues, etc. ,GANCICLOVIR ,ANTIVIRAL agents ,PURINES - Abstract
Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for long-term use. Valganciclovir, which has an oral bioavailability of 60%, has proven to be useful for prophylaxis of CMV infection in high-risk SOT recipients and for treating retinitis in persons with acquired immunodeficiency syndrome. Objective. To compare the efficacy of valganciclovir (alone or as sequential therapy after a regimen of intra- venous ganciclovir) with intravenous ganciclovir alone for preemptive therapy or treatment of CMV disease (viral syndrome or focal disease) in SOT recipients and to determine the incidence of adverse effects and relapses. Methods. In this 2-year prospective, comparative cohort study, 376 episodes of preemptive therapy or treatment of CMV disease were recorded among 334 of 3467 SOT recipients included in the Spanish Network for Research on Infection in Transplantation (RESITRA) database. Intravenous ganciclovir was the first-line treatment in 170 episodes; valganciclovir followed by intravenous ganciclovir was administered in 82 episodes, and valganciclovir alone was administered in 112 episodes. Results. Valganciclovir was used as preemptive therapy or treatment for CMV disease in 84 and 28 episodes, respectively. Duration of treatment was longer in valganciclovir recipients than in ganciclovir recipients for both preemptive therapy (21 vs. 15 days; P< .001) or viral syndrome treatment (21 vs. 18 days; P< .01). In the valganciclovir arm, 94 (83.9%) of 112 episodes were treated successfully, with no statistical difference in the success rates versus the ganciclovir arm (85.8%) or ganciclovir-valganciclovir arm (95.1%). Eighteen episodes (16.1%) treated with valganciclovir were considered to have resulted in treatment failure (because of persistent antigenemia in 4 [3.6%], on the basis of clinical decision in 7 [6.2%], and because of recurrent disease in 7 [6.2%]). There were no incidents in which valganciclovir treatment was withdrawn because of toxicity. Conclusion. Valganciclovir is safe and useful for preemptive therapy and treatment of CMV disease. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.